trending Market Intelligence /marketintelligence/en/news-insights/trending/ukyiT9GJevhOy900bKxCfA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Tracon Pharmaceuticals to sell $15M of common shares to private fund

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Tracon Pharmaceuticals to sell $15M of common shares to private fund

Tracon Pharmaceuticals Inc. agreed to sell common shares for up to $15 million to Chicago-based private fund Aspire Capital Fund LLC over a period of 30 months.

San Diego-based biotechnology company Tracon issued 1,426,579 common shares to the asset management firm as consideration for entering into the agreement.

Tracon plans to use the proceeds to advance its potential drugs pipeline and product development platform. Funds will also be used for general corporate purposes.

Under the agreement, Tracon will be eligible to make requests to Aspire Capital for the purchase of shares. Moreover, Aspire Capital cannot ask Tracon to sell any shares.

Tracon holds the right to terminate the agreement at any time without any additional cost or penalty.